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Experimental Procedures: 
General  
Chemicals and reagents were purchased from commercial suppliers (Sigma-Aldrich, VWR, 
Chem-Impex International, Alfa Aesar) and used without further purification. Multitron shakers 
(Infors) were used for cell growth. UV-vis spectra were collected on a UV1800 Shimadzu 
spectrophotometer (Shimadzu). Liquid chromatography/mass spectrometry (LCMS) was 
performed with an Agilent 1290 UPLC in line with a 6140 MS Single Quad MS detector. 
Samples were analyzed on a 2.1 × 50 mm C-18 silica column using acetonitrile as the strong 
solvent and 0.1% (v/v) acetic acid/water as the weak solvent. 
 
Cloning, heterologous expression, and protein purification 
The gene encoding PfTrpB (UNIPROT ID Q8U093) was previously codon-optimized for 
Escherichia coli and cloned into pET22(b)+ with a C-terminal 6-His-tag.
1
 Expression and 
purification protocols for the variants reported here were similar to those reported previously.
1
 
Briefly, a single colony of E.coli BL21 E. cloni Express cells (Lucigen) harboring the PfTrpB 
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plasmid was used to inoculate a 5-mL culture of Terrific Broth with 100 µg/mL ampicillin 
(TBamp) and incubated overnight at 37 C and 250 rpm. This culture was used to inoculate a 500-
mL TBamp expression culture, which was incubated at 250 rpm and 37 C for ~ 3 h or until an 
OD600 of 0.6-0.8 was reached. Cultures were chilled on ice for 20-30 min and expression was 
induced by the addition of isopropyl -D-thiogalactopyranoside (IPTG) to a final concentration 
of 1 mM. Cells continued to grow shaking at 250 rpm and 20 C for another 20 h. Cells were 
harvested by centrifugation at 4 C and 5,000g for 10 min; the pellets were frozen at -20 C until 
further use.  
Frozen cell pellets were thawed at room temperature and resuspended in 50 mM phosphate 
buffer, pH 8.0, with 20 mM imidazole and 100 mM NaCl (buffer A), with 200 µM PLP, 1 
mg/mL hen egg white lysozyme, and 0.02 mg/mL DNAse. After vortexing, cells were lysed with 
BugBuster (Novagen) at one half of the manufacturer’s recommended concentration. Lysates 
were aliquoted into 1.6-mL tubes and centrifuged at 20,000g and 4 C for 10 min and then 
incubated at 75 C for 10 min, centrifuged again as described above. The cleared, heat-treated 
lysate was applied to a 1-mL Histrap HP column (GE Healthcare). The purification was 
performed with an AKTA purifier FPLC system (GE Healthcare). PfTrpB (and variants thereof) 
eluted during a linear gradient from buffer A to buffer B (50 mM phosphate buffer with 500 mM 
imidazole and 100 mM NaCl, pH 8.0) at ≈ 140 mM imidazole. Purified enzyme was dialyzed 
into 50 mM phosphate buffer, pH 8.0, frozen in liquid N2, and stored at -80 C until further use.  
A similar procedure was used to prepare the PfTrpS complex with the following exceptions. 
PfTrpA was expressed without the 6-his tag and initially purified as a heat-treated lysate without 
the addition of PLP. The amount of TrpA and TrpB present in the lysate was estimated by SDS-
PAGE, and the heteromeric TrpS complex was formed by mixing C-His-TrpB with an 
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approximate two-fold molar excess of native TrpA. The resultant complex was purified via pull-
down by Ni-affinity chromatography on an AKTA purifier FPLC system (GE Healthcare). TrpS 
eluted during a linear gradient from buffer A (50 mM phosphate buffer with 20 mM imidazole 
and 100 mM NaCl, pH 8.0) to buffer B (same as buffer A, but with 500 mM imidazole) at ≈ 140 
mM imidazole. 
Purified protein concentrations were determined via the Bradford assay (Bio-Rad).  
 
Kinetics 
Tryptophan formation was monitored at 75 C over 1 min at 290 nm using Δε290 = 1.89 mM
-1
 
cm
-1
.
2
 The assay buffer contained 200 mM potassium phosphate pH 8.0. Previous studies 
included additional equivalents of PLP cofactor, however this was found to have no measurable 
effect on activity and was removed from the assays reported here. Michaelis constants (KMs) for 
indole were determined using a concentration range of 10–300 μM indole with the concentration 
of L-serine fixed at 20 mM. The KMs for L-serine were determined using a concentration range of 
0.3–20 mM L-serine with the concentration of indole fixed at 250 μM. Initial velocities were 
measured in duplicate or triplicate for at least six different substrate concentrations for each 
enzyme. The data were fit using an in-house non-linear least squares algorithm to the Michaelis-
Menten equation implemented in MatLab. The kcats for the overall reaction (Table 1) were 
determined from the titration of indole (above).  
Kinetic isotope effects (KIE) were measured using d3-L-Ser as described in the main text. Direct 
competition experiments for PfTrpB were conducted in triplicate using 10 mM (d3)-Ser, 1 mM 
indole, and 10 μM PfTrpB. Reactions were conducted in 0.2 M K phosphate pH 8.0 and 
incubated at 75 °C for 2 hours and quenched with an equal volume of 100% acetonitrile. The 
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ratio of L-Trp to d2-L-Trp was measured by LC-MS and integration of the extracted ion 
chromatogram at the appropriate m/z, indicating a KIE of 2.61 ± 0.08. KIEs were also 
determined by comparing initial velocities of reactions conducted with 10 mM (d3)-Ser, 0.25 
mM indole, and 0.5 μM of each PfTrpB variant or PfTrpS. Values are reported in Table 1. 
 
UV-Vis spectroscopy 
Spectra were collected between 550 and 250 nm on a UV1800 Shimadzu spectrophotometer 
(Shimadzu) using 5–60 µM of enzyme in 200 mM potassium phosphate pH 8.0 in a quartz 
cuvette. Samples were incubated at 75 °C for > 3 min to ensure a stable temperature was reached 
prior to addition of substrates. For steady-state spectra, enzyme and 1 mM indole were pre-
incubated and the reaction initiated by addition of 20 mM L-serine. The initial spectrum was 
recorded in < 15 s, prior to the consumption of indole. A second spectrum was collected after 1 
min, whereupon consumption of indole shifted the steady state to reflect only the Stage I 
intermediates of the catalytic cycle. These latter spectra matched those previously reported in the 
absence of indole or tryptophan. 
Tryptophan binding affinities were determined by titration in the spectrophotometer and 
monitoring the change in absorbance at 475 nm, corresponding to population of the E(Q 3) 
species, using 20 μM enzyme and fit to a single site binding isotherm. To increase the signal for 
PfTrpB, 60 μM was used. For PfTrpB
2B9
, experiments were performed at both 10 and 20 μM, 
which ensured that the fit value of the KD for Trp (12 μM) was not an artifact of the lower bound 
of the assay, which equals half the protein concentration.  
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Protein Crystallography 
PfTrpB
WT
 crystallization conditions were identified previously,
1
 and crystals routinely grew in 
sitting drops against a 1-mL reservoir of 15-20% PEG3350 and 0.1 M Na HEPES pH 7.85 with 
mother liquor comprised of 1.5 µL of 8.0 mg/mL PfTrpB
WT
 and 1.5 µL of well solution. Crystals 
of PfTrpB
4D11
 were inconsistently grown in similar conditions. To produce crystals for 
PfTrpB
2B9
 (and for PfTrpB
4D11
), crystallization was induced by cross-seeding with pre-formed 
seeds of PfTrpB
WT
 crystals prepared using the Seed Beed
TM
 kit (Hampton Research). Well 
solution contained 12-16% PEG3350 and 0.1 M Na HEPES pH 7.85. The mother liquor 
consisted of 1.5 μL of 10 mg/mL PfTrpB variant and 1.5 μL of seed solution. Crystals grew over 
the course of three days and were stable in the dark over several months. Ser-bound crystals were 
prepared by soaking pre-formed crystals with 250 mM L-serine dissolved in well solution for 5-
10 min. Trp-bound crystals were prepared by addition of solid Trp (~ 1-2 mg) directly onto drops 
containing pre-formed crystals and allowed to equilibrate overnight. Crystals were cryo-
protected through oil immersion in Fomblin Y (Sigma) and flash frozen in liquid N2 until 
diffraction. Data were collected remotely at the Stanford Synchrotron Radiation Laboratories on 
beamline 12-2. Crystals routinely diffracted at or below 2.0 Å, and the data were integrated and 
scaled using XDS
3
 and AIMLESS.
4
 Structures were solved using molecular replacement with 
PHASER, as implemented in CCP4.
5,6
 The search model comprised of a single monomer of 
PfTrpB
WT
 (PDB ID: 5DVZ), PfTrpB
WT
-Ser (PDB ID: 5DW0), or PfTrpB
WT
-Trp (PDB ID: 
5DW3) where each of the mutated residues was deleted, the ligands and waters removed, and the 
whole model subject to ten cycles of geometric idealization in Refmac5. Model building was 
performed in Coot
7
 beginning with data processed at 2.4 Å, followed by subsequent inclusion of 
increasingly higher resolution shells of data with relaxed geometric constraints. Refinement was 
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performed using REFMAC5
8
 and resolution cutoffs were applied when incorporation of 
additional data caused Rfree in the final bin to exceed 0.4; this criteria conformed to the 
crystallographic cutoff where CC1/2 > 0.3 along the strongest axis of diffraction.
4,9
 The 
MolProbity server was used to identify rotamer flips, clashes, and calculate Ramachandran 
statistics.
10
 After the protein, ligand, and solvent atoms were built, TLS operators were added to 
refinement, which resulted in substantial improvements in R free for the final models. 
Crystallographic and refinement statistics are reported in Table S1. 
 
Supplemental Figures 
 
Figure S1. Trp binding isotherms for TrpB enzymes. Representative titration of Trp with each enzyme. 
The change in absorbance was recorded at 475 nm, corresponding to the E(Q 3) intermediate. A non-
linear fit to a single-site binding model for all titrations were performed in Matlab.  
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Figure S2. Comparison of steady-state and Trp-bound spectra of TrpB enzymes. Spectra were collected 
with 20-60 μM enzyme and are normalized with the absorbance of E(Ain) set at 1.0 for easy comparison  
(black). The steady-state spectra are shown in orange and are identical to those shown in Figure 2. The 
spectra of the Trp-bound protein at equilibrium are shown in purple and are identical to those shown in 
Figure 3. For PfTrpB and PfTrpB2G9, the peak at steady state has a significant population of E(Aex 1) that 
convolutes direct comparison.  
 
Figure S3. Comparison of native TrpBs in the E(Ain) state. In the native TrpS complex, TrpB (red) is in an 
extended open conformation. This is closely matched by the conformation of isolated TrpB with β -
MeTrp (green spheres) in a tunnel connecting the two subunits, with an RMSD = 0.36 Å 2 between the 
backbone atoms of TrpB. In contrast, isolated TrpB without any ligands bound forms a non-extended 
‘open’ conformation (gray).  
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Figure S4. Structural comparison of PfTrpB (gray), PfTrpB4D11 (blue, 4D11), and PfTrpB2B9 (red, 2B9) in the 
E(Ain) state. (a) The I16V mutation is present in 2B9, and E17G is in both 4D11 and 2B9. (b) I68V is 
present in both 4D11 and 2B9. (c) F95L is present in 2B9. (d) T292S is present in both 4D11 and 2B9. This 
residue hydrogen bonds with D300 in the 2B9 structure. See main te xt for further detail. (e) F274 is 
present in 4D11 and 2B9. (f) T321A is present in 4D11 and 2B9. This mutation is associated with a small 
readjustment of the L257 residue, but no further changes are observable within the region. (g) V384A is 
present in 2B9 and is located near the C-terminus of the protein where there is generally high 
conformational variability. Minor variation is observed between prot omers of a given protein and a 
single, representative chain is shown here for clarity.  
 
 
Figure S5. Structural comparison of PfTrpB (gray), PfTrpB4D11 (blue, 4D11), and PfTrpB2B9 (red, 2B9) with 
Ser bound in the E(Aex1) state. (a) The I16V mutation is present in 2B9, and E17G is in both 4D11 and 
2B9. (b) I68V is present in both 4D11 and 2B9. (c) F95L is present in 2B9. (d) T292S is present in both 
4D11 and 2B9. (e) F274 is present in 4D11 and 2B9. (f) T321A is present in 4D11 and 2B9. This mutation 
is associated with a small readjustment of the L257 residue, but no additional change is observable 
within the region. (g) V384A is present in 2B9 and is located near the C -terminus of the protein where 
there is generally high conformational variability. Minor variation is observed between protomers of a 
given protein and a single, representative chain is shown here for clarity.  
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Figure S6. Structural comparison of PfTrpB (gray), PfTrpB4D11 (blue) and PfTrpB2B9 (magenta) in the 
E(Aex1) state shows no observable differences. PDB IDs: 5DW0, 6AMH, and 5VM5, respectiv ely 
 
 
 
Figure S7. Structural comparison of PfTrpB (gray), PfTrpB4D11 (blue, 4D11), and PfTrpB2B9 (red, 2B9) in the 
E(Ain) state with Trp non-covalently bound in the active site. (a) The I16V mutation is present in 2B9, 
and E17G is in both 4D11 and 2B9. (b) I68V is present in both 4D11 and 2B9. (c) F95L is present in 2B9. 
(d) T292S is present in both 4D11 and 2B9. This residue hydrogen bonds with D300 in each structure (e) 
F274 is present in 4D11 and 2B9. (f) T321A is present in 4D11 and 2B9. In this state, the N267 side chain 
showed multiple conformations, but no additional perturbations in the neighboring residues. (g) V384A 
is present in 2B9 and is located near the C-terminus of the protein where there is generally high 
conformational variability. Minor variation is observed between protomers of a given protein and a 
single, representative chain is shown here for clarity.  
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Figure S8. Comparison of the steady-state distribution of intermediates with L-Ser added to PfTrpB4D11 
(blue) and PfTrpB2B9
 
(red) at 25 °C. Spectra are normalized with the E(Ain) absorbance (black) at 412 nm 
set to 1.0 for each enzyme.  
 
 
 
Figure S9. Comparison of the E(A-A) state of PfTrpB2B9 (gray, PDB ID: 5VM5 ) and StTrpS (green, PDB ID: 
4HN4) shows a nearly identical active site. 
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Figure S10. Structural comparison of native PfTrpB2B9-E(Aex2) with StTrpS
βK87T-E(Aex2). (a) The active site 
of PfTrpB2B9 with Trp covalently bound as the E(Aex2) intermediate. Hydrogen bonds to the carboxylate 
and indole N1 of Trp are shown in yellow. L161 is observed in a non-standard eclipsed rotamer. The next 
step in the catalytic cycle is transimination with the active site lysine, K82, with the trajectory indicated 
in orange dashes. (b) The active site of the catalytically inactive StTrpSβK87T with tryptophan covalently 
bound as the E(Aex2) intermediate and hydrogen bonds indicated (PDB ID: 2TYS). (c) Overlay of the two 
structures. Introduction of the K87T mutation appears to cause two principle active site distortions. 
First, the E(Aex2) shifts location and the carboxylate rotates ~ 40°, which alters its hydrogen bond 
interactions. Second, repositioning of the Trp allows the L161 residue (Pf numbering) to relax away from 
its eclipsed conformation into a standard staggered rotamer.  
 
 
Figure S11. Comparison of substrate and product bound PfTrpB structures. Average distance and 
standard deviation of each residue of the four protomers of a given structure from the extended-open 
conformation. PfTrpB, no ligands, E(Ain), grey (PDB ID: 5DVZ). PfTrpB, Ser-bound E(Aex1), cyan (PDB ID: 
5DW0). PfTrpB, Trp-bound, E(Ain), purple (PDB ID: 5DW3). 
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Figure S12. Comparison of B-factor with conformational heterogeneity in PfTrpB2B9. The heterogeneity is 
calculated as the standard deviation of the distance of each reside from the extended -open 
conformation. As this parameter is an average across the protein, it is the same in each panel. Chains 
are therefore distinguished by the B-factor at Cα of each residue. The plots show that B-factors are 
weakly correlated with the observed heterogeneity.  
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Table S1. X-Ray crystallographic data collection and refinement statistics 
 PDB ID  6AMC 6AMH 6AMI 6AM7 5VM5 6AM9 6AM8 
 Protein  PfTrpB4D11 PfTrpB4D11 PfTrpB4D11 PfTrpB2B9 PfTrpB2B9 PfTrpB2B9 PfTrpB2B9 
 Ligand  N/A L-Serine L-Trp N/A L-Serine L-Serine L-Trp 
 State of PLP  E(Ain) E(Aex1) E(Ain) E(Ain) 
E(Aex1) x3, 
E(A-A) x1 
E(Aex1) x1, 
E(A-A) x3 
E(Ain) x2, 
E(Aex2) x2 
Data Collection 
 Space group  P212121 P212121 P212121 P212121 P212121 P212121 P212121 
 Cell dimensions (Å)  
a,b,c = 
84.4, 110.7, 
160.4 
a,b,c = 
84.8, 109.6, 
160.9 
a,b,c = 
84.7, 109.9, 
160.3 
a,b,c = 
84.0, 107.8, 
159.8 
a,b,c = 
83.1, 108.7, 
160.5 
a,b,c = 
87.5, 109.1, 
160.5 
a,b,c = 
82.2, 106.0,  
158.7 
 Cell angles  α = β = γ = 90° α = β = γ = 90° α = β = γ = 90° α = β = γ = 90° α = β = γ = 90° α = β = γ = 90° α = β = γ = 90° 
 Wavelength (Å)  0.9795 0.9795 0.9795 0.9795 0.9795 0.9795 0.9795 
 Beamline  SSRL 12.2 SSRL 12.2 SSRL 12.2 SSRL 12.2 SSRL 12.2 SSRL 12.2 SSRL 12.2 
 Resolution (Å)  40 – 1.93 40 – 1.63 40 – 1.97 40 – 1.47 40 – 1.67 40 – 2.09 40 – 1.83 
 Last bin (Å)  (1.96 – 1.93) (1.66 – 1.63) (2.00– 1.97) (1.49 – 1.47) (1.70 – 1.67) (2.13 – 2.09) (1.86 – 1.83) 
 No. observations  771,083 1,251,845 715,034 2,033,273 1,686,757 614,681 886,235 
 Completeness (%)  99.7 (99.61) 99.9 (99.9) 99.9 (99.9) 98.8 (77.3) 99.7 (99.7) 99.6 (99.7) 99.2 (88.3) 
 Rpim  0.026 (0.547) 0.035 (1.191) 0.047 (1.338) 0.031 (0.915) 0.043 (0.894) 0.030 (0.739) 0.036 (0.864) 
 CC(1/2)  0.998 (0.605) 0.999 (0.327) 0.999 (0.360) 0.999 (0.284) 0.998 (0.638) 0.998 (0.695) 0.999 (0.597) 
 I/σI  15.4 (1.3) 12.2 (0.7) 11.4 (0.8) 12.1 (0.8) 10.7 (0.9) 13.5 (0.9) 11.5 (0.9) 
 Redundancy  6.7 (6.5) 6.7 (6.8) 6.7 (6.9) 8.4 (4.8) 10.0 (10.2) 6.7 (6.9) 7.3 (4.6) 
Refinement 
 Total no. of reflections  108,623 175,962 100,105 229,981 159,409 86,509 115,028 
 Total no. of atoms  11,776 12,380 12,210 12,528 12,315 11,601 12,210 
 Final bin (Å)  (1.98 – 1.93) (1.67 – 1.63) (2.02 – 1.97) (1.51 – 1.47) (1.71 – 1.67) (2.14-2.09) (1.88-1.83) 
 Rwork (%)  22.6 (35.8) 20.7 (37.3) 22.1 (39.0) 19.9 (36.2) 19.5 (39.7) 21.4 (41.4) 20.2 (38.4) 
 Rfree (%)  25.6 (37.9) 23.3 (39.1) 25.9 (39.5) 21.3 (37.2) 22.4 (39.9) 24.4 (39.7) 23.1 (39.8) 
 Average B factor (Å2)  50.4 33.4 45.5 24.5 29.8 60.1 39.6 
 Ramachandran plot  
  Favored, % 
 98.1 97.9 97.8 98.1 98.5 97.7 97.8 
  Allowed, %  99.9 99.7 99.9 99.8 99.9 99.8 99.7 
  Outliers, %  0.1 0.3 0.1 0.2 0.1 0.2 0.3 
Values in parenthesis are for the highest resolution shell. Rmerge is Σ|Io – I| / ΣIo , where Io is the intensity of an individual reflection, and I is the 
mean intensity for multiply recorded reflections. Rwork is Σ||Fo – Fc|| / Fo, where Fo is an observed amplitude and Fc a calculated amplitude. Rfree 
is the same statistic calculated with a 5% subset of the data that was included in refinement.  
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